Skip to content
Triangle logo TriangleGet started
← Full study record

NCT06655818 · BASELINE

Baseline characteristics

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM · Source last updated 2025-03-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      4
    units
    Participants
groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).
    id
    BG000
    title
    1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.83
          value
          70.0
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    YEAR
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      Males and Females
    description
    Gender categories (with 0\<n\<11) are combined into 'Males and Females' category to maintain participant confidentiality and privacy as the study is evaluating a rare disease.
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex/Gender, Customized
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      Others
    description
    Race categories (with 0\<n\<11) are combined into 'Others' category to maintain participant confidentiality and privacy as the study is evaluating a rare disease.
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      4
    units
    Participants
groups
  1. description
    Participants with Relapsed/Refractory Multiple Myeloma (RRMM) received 1.9 milligram (mg)/kilogram (kg) belantamab mafodotin intravenous (IV) infusion as powder for solution once every 3 weeks (Q3W) infused over 30- 60 minutes on day 1 of 21-day cycles in combination with 500 mg dostarlimab as a 30-minute IV infusion 1 hour after belantamab mafodotin end of infusion (EOI) on day 1 of 21-day cycles (Q3W).
    id
    BG000
    title
    1.9 mg/kg Belantamab Mafodotin + 500mg Dostarlimab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.83
          value
          70.0
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    YEAR
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      Males and Females
    description
    Gender categories (with 0\<n\<11) are combined into 'Males and Females' category to maintain participant confidentiality and privacy as the study is evaluating a rare disease.
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex/Gender, Customized
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          4
      title
      Others
    description
    Race categories (with 0\<n\<11) are combined into 'Others' category to maintain participant confidentiality and privacy as the study is evaluating a rare disease.
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Race/Ethnicity, Customized
    unit Of Measure
    Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice